SEC Form 4/A · accession 0001104659-18-072488
Aridis Pharmaceuticals, Inc. · ARDS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Fred Kurland
Officer — Chief Financial Officer
Period of report
Dec 5, 2018
Accepted (ET)
Dec 12, 2018 · 11:39 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001614067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2,F1 | $8.50 | Dec 5, 2018 | A | 17,000 | A | — | Dec 5, 2028 | Common Stock | 17,000 | 39,574 | D |
Explanation of responses
- F1The shares underlying this stock option vest as follows: in equal annual installments over the 48 months following the date of grant.
- F2Due to a clerical error, the reporting person is filing this Amendment to correct the amount of derivative securities beneficially owned following the reported transaction from 40,024 to 39,574.